title: Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
authors.affiliation: Myriad Genetic Laboratories, Inc, Salt Lake City, UT, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Saam
authors.forename: Gregory C
authors.initials: GC
authors.lastname: Critchfield
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Hamilton
authors.forename: Benjamin B
authors.initials: BB
authors.lastname: Roa
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Wenstrup
authors.forename: Rajesh R
authors.initials: RR
authors.lastname: Kaldate
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D000068258:Bevacizumab; D001830:Body Surface Area; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D057285:Precision Medicine
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin